Trial · NCT02011945
Outcomes24
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Dose Limiting Toxicities (DLT) | Week 3 to week 6 | All Treated Participants | Number of Incidence | NUMBER |
| PRIMARY | Incidence of Adverse Events (AEs) | Initiation of study drug to discontinuation of nivolumab stop date + 100 days or discontinuation of dasatinib + 30 days | All Treated Participants | Number of Adverse Events | NUMBER |
| PRIMARY | Incidence of Serious Adverse Events (SAEs) | Initiation of study drug to within 100 days of discontinuation of nivolumab dosing and 30 days of dasatinib dosing | All Treated Participants | Number of Adverse Events | NUMBER |
| PRIMARY | Incidence of Change From Baseline in Clinical Laboratory Tests: Hematology | Up to 40 Months | All Treated Participants | Participants | NUMBER |
| PRIMARY | Incidence of Abnormalities in Clinical Laboratory Tests: Liver Tests | Up to 40 Months | All Treated Participants with at least one treatment measure | Participants | NUMBER |
| PRIMARY | Incidence of Laboratory Abnormalities in Specific Thyroid Tests | Up to 40 Months | All Treated Participants | Number of Incidences | NUMBER |
| SECONDARY | Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), No Prior Dasatinib Participants | upto 36 Months | All treated Participants, CML-CP no prior Dasatinib participants | Percentage of Participants | NUMBER |
| SECONDARY | Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), Prior Dasatinib Participants | upto 36 Months | All treated Participants, CML-CP prior Dasatinib participants | Percentage | NUMBER |
| SECONDARY | Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Advanced Phase (CML-AP) Participants | upto 36 Months | All treated Participants, CML-AP Participants | Percentage | NUMBER |
| SECONDARY | Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), No Prior Dasatinib Participants | upto 36 Months | All treated Participants, CML-CP no prior Dasatinib participants | Percentage | NUMBER |
| SECONDARY | Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), Prior Dasatinib Participants | upto 36 Months | All treated Participants, CML-CP prior Dasatinib participants | Percentage | NUMBER |
| SECONDARY | Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Advanced Phase (CML-AP) Participants | upto 36 Months | All treated Participants, CML-AP Participants | Percentage | NUMBER |
| SECONDARY | Time to Major Molecular Response (MMR) - CML-CP No Prior Dasatinib Participants | Up to 36 Months | CML-CP No Prior Dasatinib Subjects | Months | MEDIAN |
| SECONDARY | Time to Major Molecular Response (MMR) - CML-CP Prior Dasatinib Participants | Up to 36 Months | CML-CP Prior Dasatinib participants | Months | MEDIAN |
| SECONDARY | Time to Major Molecular Response (MMR) - CML-AP Participants | Up to 36 Months | CML-AP Participants | Months | MEDIAN |
| SECONDARY | Duration of Major Molecular Response (MMR) - CML-CP No Prior Dasatinib Participants | Up to 36 Months | CML-CP No Prior Dasatinib participants | Months | MEDIAN |
| SECONDARY | Duration of Major Molecular Response (MMR) - CML-CP Prior Dasatinib Participants | Up to 36 Months | CML-CP Prior Dasatinib Participants | Months | MEDIAN |
| SECONDARY | Duration of Major Molecular Response (MMR) - CML-AP Participants | Up to 36 Months | CML-AP Participants | Months | MEDIAN |
| SECONDARY | Time to Molecular Response 4.5(MR4.5) - CML-CP No Prior Dasatinib Participants | Up to 36 Months | CML-CP No Prior Dasatinib Participants | Months | MEDIAN |
| SECONDARY | Time to Molecular Response 4.5(MR4.5) - CML-CP Prior Dasatinib Participants | Up to 36 Months | CML-CP Prior Dasatinib Participants | Months | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02011945/outcomes